All In Biotech

Drug Trial Radar · NCT00542802

Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis

Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis

Last checked: Nov 20, 2026Latest source record: May 30, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

630

Planned (sponsor's estimate)

Start

Sep 2007

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Scienze Neurologiche OspedaliereAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The principal purpose of the study is to determine the efficacy and safety of Levetiracetam versus Carbamazepine, intended as the number of patients free from crisis during the whole period of treatment, in patients affected by post stroke late onset crisis.

Conditions

  • Epileptic Seizures
  • Stroke

Interventions

  • LevetiracetamDrug

    Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events

  • CarbamazepineDrug

    Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number of patients free from post stroke recurrent crisisTime frame: one year

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Policlinico Umberto I

    Ancona, Italy · Not yet recruiting

  • Ospedale A. Perrino

    Brindisi, Italy · Recruiting

  • Ospedale Cannizzaro

    Catania, Italy · Not yet recruiting

  • Ospedale San Martino

    Genova, Italy · Recruiting

  • Ospedale Civile Imperia ASL 1

    Imperia, Italy · Recruiting

  • Ospedale A. Cardarelli-

    Naples, Italy · Recruiting

  • Ospedale Cardarelli

    Naples, Italy · Not yet recruiting

  • Ospedale Civico

    Palermo, Italy · Not yet recruiting

  • Osp. Guglielmo da saliceto

    Piacenza, Italy · Recruiting

  • Arcispedale S. Maria Nuova

    Reggio Emilia, Italy · Recruiting

  • Ospedale SS. Annunziata - Ospedale Civile

    Taranto, Italy · Recruiting

  • Ospedale Molinette-Università di Torino

    Torino, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Trieste

    Trieste, Italy · Recruiting

  • Ospedale S. Giacomo

    Novi Ligure, AL, Italy · Not yet recruiting

  • Ospedale S. Croce E Carle

    Cuneo, CN, Italy · Not yet recruiting

  • Ospedale S. Martino

    Genova, GE, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, MI, Italy · Recruiting

  • USL 2 Ospedale B.G. Villa

    Città della Pieve, PG, Italy · Not yet recruiting

  • Ospedale Civile San Giovanni Battista di Foligno

    Foligno, PG, Italy · Recruiting

  • Ospedale Santa Maria della Misericordia

    Sant'Andrea Delle Fratte, PG, Italy · Not yet recruiting

  • Istituto Neurologico C. Mondino

    Pavia, PV, Italy · Not yet recruiting

  • Ospedale Guzzardi

    Vittoria, RG, Italy · Recruiting

  • Ospedale Di Portogruaro

    Portogruaro, VE, Italy · Recruiting

  • Ospedale Civile

    Vibo Valentia, VV, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.